Investment Rating - The industry investment rating is "Increase Holding" [2][6] Core Insights - The National Healthcare Security Administration has released a draft guideline for the pricing of laboratory medical services, aiming to standardize and integrate existing pricing projects into 573 items, covering major testing areas such as biochemical testing, immunological testing, microbiological testing, nucleic acid testing, tumor marker testing, and routine examinations [5] - The guideline establishes a unified framework for pricing projects, addressing long-standing issues of inconsistent naming and pricing across different regions, which is expected to enhance the standardization of pricing projects and facilitate future cross-regional settlement by medical insurance [5] - The pricing authority is delegated to local medical insurance departments, implementing a maximum price management mechanism, allowing local departments to set prices based on regional medical resources and cost structures [5] - The guideline continues the "separation of technology and consumables" reform direction, allowing for additional charges for innovative testing projects while standardizing the pricing structure [5] - The guideline lists several Alzheimer's disease (AD) related neurobiomarker testing projects, providing a pricing framework that could facilitate the commercialization of AD blood biomarker testing [5] Summary by Sections Industry Overview - The industry comprises 504 listed companies with a total market value of 69,495.74 billion and a circulating market value of 63,676.63 billion [2] Pricing Structure - The guideline specifies that the pricing of laboratory medical services will be based on human resource consumption and basic material resource consumption, with a focus on standardizing the pricing structure and reducing non-compliant profit margins [5] - The guideline allows for additional charges based on different testing methodologies, with specific standards to be set by local medical insurance departments [5] Market Opportunities - The guideline's focus on standardizing pricing and the inclusion of AD-related tests is expected to create clearer pathways for commercialization in the innovative testing sector, particularly for companies with existing product reserves in AD testing [5]